A Multinational, Prospective, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Treatment of Patients With Severe Community-Acquired Pneumonia

Trial Profile

A Multinational, Prospective, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Treatment of Patients With Severe Community-Acquired Pneumonia

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Moxifloxacin (Primary) ; Moxifloxacin (Primary) ; Ceftriaxone; Levofloxacin; Levofloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms MOTIV
  • Sponsors Bayer
  • Most Recent Events

    • 15 May 2008 Results have been published in an article in Clinical Infectious Diseases 2008.
    • 08 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top